Creative Commons source reading · Multiple sclerosis and neuroimmunology
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.
Jyh Yung Hor; Nasrin Asgari; Ichiro Nakashima; Simon A Broadley; M Isabel Leite; Najib Kissani; Anu Jacob; Romain Marignier; Brian G Weinshenker; Friedemann Paul; Sean J Pittock; Jacqueline Palace; Dean M Wingerchuk; Jacinta M Behne; Michael R Yeaman; Kazuo Fujihara
Originally published in Frontiers in neurology · 2020-06-26
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease of the central nervous system, manifesting clinically as optic neuritis, myelitis, and certain brain and brainstem syndromes. Cases clinically diagnosed as NMOSD may include aquaporin 4 (AQP4)-antibody-seropositive autoimmune astrocytopathic disease, myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive inflammatory demyelinating disease, and double-seronegative disease. AQP4-antibody disease has a high female-to-male ratio (up to 9:1), and its mean age at onset of ~40 years is later than that seen in multiple sclerosis. For MOG-antibody disease, its gender ratio is closer to 1:1, and it is more common in children than in adults. Its clinical phenotypes differ but overlap with those of AQP4-antibody disease and include acute disseminated encephalomyelitis, brainstem and cerebral cortical encephalitis, as well as optic neuritis and myelitis. Double-seronegative disease requires further research and clarification. Population-based studies over the past two decades report the prevalence and incidence of NMOSD in different populations worldwide.
Conclusion
There appears to be varying prevalence rates of NMOSD, most cases of which are AQP4-antibody-positive cases, among the different racial groups worldwide, with East Asians and Blacks having a higher prevalence than Whites. In most regions, these prevalence rates are lower than that of MS. In AQP4-antibody-positive NMOSD, female preponderance is definite (up to 90%) and the majority of the cases are adults. Moreover, the clinical features of NMOSD and disability accrual may be influenced by onset age and race.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
